» Articles » PMID: 18426896

Activities and Ultrastructural Effects of Antifungal Combinations Against Simulated Candida Endocardial Vegetations

Overview
Specialty Pharmacology
Date 2008 Apr 23
PMID 18426896
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

In vitro pharmacodynamic model (PDM) simulation of serum antifungal concentrations may predict the value of combination antifungal regimens against Candida sp. endocarditis. We investigated the effects of combinations of flucytosine (5FC), micafungin (Mica), and voriconazole (Vor) against Candida-infected human platelet-fibrin clots, used as simulated endocardial vegetations (SEVs). Single clinical bloodstream isolates of Candida albicans, Candida glabrata, Candida parapsilosis, and Candida tropicalis were used. All four isolates were susceptible to 5FC, while C. glabrata was resistant to Vor and C. tropicalis had a paradoxical resistance phenotype to Mica. The SEVs were prepared with an initial inoculum of 1 x 10(6) CFU/g of SEV and added to a PDM, which utilized yeast nitrogen broth-2% glucose and incubation at 35 degrees C and simulated antifungal pharmacokinetic profiles. Fungal densities in the SEVs were determined in quadruplicate over 72 h. Scanning electron microscopy (SEM) was used to evaluate treatment and control SEVs. Vor was the least active single agent against all Candida spp. except for C. parapsilosis, where it was comparable to Mica. In contrast, 5FC was the most active against all Candida spp. except for C. tropicalis, where it was comparable to Mica. The combination of 5FC plus Vor was superior to either agent alone against C. parapsilosis. The combination of Vor plus Mica was inferior to the use of Mica alone against C. tropicalis. The triple combination of 5FC plus Vor plus Mica was no better than single or dual agents against any of the Candida spp. The ultrastructural features of infected SEVs were unique for each Candida sp., with C. parapsilosis in particular manifesting friable biofilm clusters. In general, 5FC and Mica were superior in their rates and extents of fungal burden reduction compared to Vor against Candida-infected SEVs. Evaluation of 5FC and Mica in animal models of Candida endocarditis is warranted.

Citing Articles

Candida endocarditis: Update on management considerations.

Jamil Y, Akinleye A, Mirzaei M, Lempel M, Farhat K, Pan S World J Cardiol. 2023; 15(10):469-478.

PMID: 37900901 PMC: 10600790. DOI: 10.4330/wjc.v15.i10.469.


Antifungal Combinations against Species: From Bench to Bedside.

Fioriti S, Brescini L, Pallotta F, Canovari B, Morroni G, Barchiesi F J Fungi (Basel). 2022; 8(10).

PMID: 36294642 PMC: 9605143. DOI: 10.3390/jof8101077.


The future of biofilm research - Report on the '2019 Biofilm Bash'.

Coenye T, Kjellerup B, Stoodley P, Bjarnsholt T Biofilm. 2021; 2:100012.

PMID: 33447799 PMC: 7798458. DOI: 10.1016/j.bioflm.2019.100012.


Micafungin for Candida albicans pacemaker-associated endocarditis: a case report and review of the literature.

Tascini C, Bongiorni M, Tagliaferri E, Di Paolo A, Flammini S, Soldati E Mycopathologia. 2012; 175(1-2):129-34.

PMID: 23073824 DOI: 10.1007/s11046-012-9591-2.


Successful surgical intervention for the management of endocarditis due to multidrug resistant Candida parapsilosis: case report and literature review.

Kumar J, Fish D, Burger H, Weiser B, Ross J, Jones D Mycopathologia. 2011; 172(4):287-92.

PMID: 21537953 DOI: 10.1007/s11046-011-9430-x.


References
1.
Theuretzbacher U, Ihle F, Derendorf H . Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006; 45(7):649-63. DOI: 10.2165/00003088-200645070-00002. View

2.
Wagner C, Graninger W, Presterl E, Joukhadar C . The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology. 2006; 78(4):161-77. DOI: 10.1159/000096348. View

3.
Meletiadis J, Verweij P, TeDorsthorst D, Meis J, Mouton J . Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med Mycol. 2005; 43(2):133-52. DOI: 10.1080/13693780410001731547. View

4.
Pappas P . Invasive candidiasis. Infect Dis Clin North Am. 2006; 20(3):485-506. DOI: 10.1016/j.idc.2006.07.004. View

5.
Flecknell P . Replacement, reduction and refinement. ALTEX. 2002; 19(2):73-8. View